Robust long‐term survival data have transformed the prognosis of metastatic melanoma. For combination therapy with immune checkpoint inhibitors (ICIs), 10‐year melanoma‐specific survival rates now exceed 50 %, and durable disease control is achievable in a substantial proportion of patients, including those with brain...
Markus Reitmajer, S. Dugas-Breit, C. Blomen et al.· Journal der Deutschen Dermat...· 0 citations
It is demonstrated that methylation-based models can capture both diagnostic identity and clinically relevant disease stratification, supporting DNA methylation as a promising biomarker for further validation and potential clinical translation.
J. Winterstein, L. Heinlein, G. Raddatz et al.· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.